Targeted Breast Cancer Therapy: How Trastuzumab, Abemaciclib, and Alpelisib Work and Who They Help

Table of Contents

• Key Points
• Background: Why Breast Cancer Is Not One Disease
• How Breast Cancer Is Classified by Molecular Subtype
• The Three Key Signaling Pathways: HER2, CDK4/6, and PI3K
• How This Review Was Conducted
• Trastuzumab: Targeting HER2-Positive Breast Cancer
• Key Clinical Trials of Trastuzumab
• Resistance to Trastuzumab
• Safety and Side Effects of Trastuzumab
• Abemaciclib: Targeting the Cell Cycle in Hormone Receptor-Positive Cancer
• Alpelisib: Targeting the PI3K Pathway
• The Challenge of Treatment Resistance
• What This Means for Patients
• Limitations of the Evidence
• Recommendations and Future Directions
• Frequently Asked Questions
• Source Information

Key Points

• Trastuzumab remains the foundation of treatment for HER2-positive breast cancer, improving survival in both early-stage and metastatic disease.
• Abemaciclib, a CDK4/6 inhibitor, improves outcomes in hormone receptor-positive disease by enhancing endocrine therapy and prolonging progression-free survival.
• Alpelisib benefits patients whose tumors carry a PIK3CA mutation when combined with endocrine therapy, highlighting the importance of genomic testing.
• Molecular testing now guides treatment selection, and resistance mechanisms limit long-term success, supporting liquid biopsy monitoring and adaptive trial designs.
• The authors emphasize that molecular diagnostics are central to clinical decision-making, including patient selection, understanding resistance, and sequencing strategies.

Background: Why Breast Cancer Is Not One Disease

Breast cancer is the most frequently diagnosed cancer among women worldwide. It remains one of the leading causes of cancer-related death. Despite improvements in screening, early detection, and systemic treatment, the global burden of this disease remains substantial. This burden highlights the ongoing need for treatments guided by tumor biology.

Over the past two decades, major advances in molecular biology and genomic profiling have changed how researchers understand breast cancer. What was once considered a relatively uniform disease defined mainly by tissue appearance is now recognized as a heterogeneous group of malignancies. These malignancies have distinct molecular signatures, signaling pathways, and clinical behaviors.

This growing knowledge has provided critical insights into how tumors begin, how they progress, and how they become resistant to treatment. These insights have enabled the development of targeted therapies. Targeted therapies are drugs designed to selectively block specific oncogenic signaling networks — the communication systems inside cells that drive cancer growth.

How Breast Cancer Is Classified by Molecular Subtype

Current molecular classification systems divide breast cancer into clinically and biologically relevant subtypes. The most common categories are:

• Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative tumors — the most common subtype, largely driven by estrogen receptor-mediated signaling
• HER2-positive disease — defined by amplification or overexpression of the ERBB2 gene, associated with increased proliferative capacity and historically poorer outcomes before targeted therapy existed
• Triple-negative breast cancer (TNBC) — defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression

Within HR-positive disease, Luminal B tumors represent a biologically heterogeneous subgroup. This subgroup includes both HER2-negative cancers with a high proliferative index (measured by an elevated Ki-67 marker) and HER2-positive tumors that also express hormone receptors. These differences reflect variations in prognosis and treatment sensitivity.

Triple-negative breast cancer is characterized by pronounced genomic instability, an elevated mutational burden, and substantial intratumoral heterogeneity. These features underlie its aggressive clinical behavior, higher risk of early recurrence, and limited availability of durable targeted treatment options. At the same time, these features provide a biological rationale for emerging therapeutic approaches. Such approaches include immune checkpoint inhibition and therapies targeting DNA damage response.

More recently, additional biological subsets such as HER2-low breast cancer have been recognized. This recognition reflects the increasing complexity of breast cancer classification and its therapeutic implications. HER2-low tumors are defined by low levels of HER2 expression. This typically corresponds to an immunohistochemistry (IHC) score of 1+ or 2+ in the absence of HER2 gene amplification by in situ hybridization (ISH). This subgroup has gained clinical relevance with the arrival of novel HER2-targeted antibody-drug conjugates. These conjugates have demonstrated meaningful activity in this previously unaddressed population.

The Three Key Signaling Pathways: HER2, CDK4/6, and PI3K

Among the molecular pathways that play central roles in breast cancer biology, three have emerged as particularly important therapeutic targets. These are the HER2 pathway, the cyclin-dependent kinases 4 and 6 (CDK4/6) pathway, and the phosphatidylinositol 3-kinase (PI3K) signaling cascade.

These pathways regulate essential cellular processes. These processes include proliferation, survival, metabolic signaling, and cell cycle progression. When these signaling networks become dysregulated, they can drive tumor formation and contribute to disease progression and resistance to therapy.

Importantly, alterations in these pathways define clinically actionable molecular subsets of breast cancer. For this reason, these pathways have become the focus of targeted therapeutic development.

Despite the substantial clinical benefit associated with CDK4/6 inhibitors such as abemaciclib, both intrinsic and acquired resistance remain major clinical challenges. Intrinsic resistance means the tumor does not respond to treatment from the start. Acquired resistance means the tumor initially responds but later stops responding.

Mechanisms of resistance include loss of retinoblastoma protein (RB1) function, which disrupts cell cycle control. Resistance also involves activation of compensatory signaling pathways, including fibroblast growth factor receptor (FGFR) signaling and the PI3K/AKT/mTOR axis. These compensatory pathways enable continued tumor proliferation despite CDK4/6 inhibition.

These molecular alterations highlight the dynamic nature of tumor evolution. They also support the emerging role of liquid biopsy approaches, including circulating tumor DNA (ctDNA) testing. Liquid biopsy allows real-time monitoring of resistance mechanisms and treatment adaptation.

How This Review Was Conducted

The authors conducted a structured literature search using the PubMed and Scopus databases. They identified relevant English-language publications published between 2006 and March 2026. The starting year was selected to encompass early translational and clinical investigations of targeted therapies. These investigations preceded or coincided with the subsequent regulatory approvals of these drugs.

Search terms included combinations of the following: "breast cancer," "trastuzumab," "abemaciclib," "alpelisib," "HER2," "CDK4/6," "PI3K," "immune checkpoint inhibitors," "targeted therapy," and "combination therapy."

Eligible studies comprised phase II and III prospective trials, randomized controlled trials, registration-directed studies, meta-analyses, and clinically informative prospective cohort studies evaluating these agents. The authors gave priority to randomized trials and pivotal studies supporting regulatory approvals. They considered large real-world cohorts and retrospective analyses when these provided meaningful insights into treatment outcomes, safety, or therapeutic sequencing.

The schematic figures included in the manuscript were created by the authors using graphical software. This software may incorporate artificial intelligence-assisted functionalities to support visualization. All scientific content, interpretation, and final figure design were critically reviewed and approved by the authors, who take full responsibility for the accuracy and originality of the material.

Trastuzumab: Targeting HER2-Positive Breast Cancer

HER2 overexpression or gene amplification occurs in approximately 15-20% of breast cancers. This alteration is associated with aggressive tumor biology and unfavorable prognosis in the absence of targeted intervention.

Trastuzumab is a humanized monoclonal antibody directed against the extracellular domain of the HER2 receptor. A monoclonal antibody is a laboratory-made protein that binds to a specific target. Trastuzumab represents a prototypical targeted biologic that has fundamentally reshaped the natural history of HER2-positive breast cancer.

As an IgG1 antibody, trastuzumab exerts antitumor activity through multiple complementary mechanisms:

• Inhibition of ligand-independent HER2 signaling
• Prevention of receptor dimerization (the pairing of receptors that activates growth signals)
• Promotion of receptor internalization and degradation
• Engagement of immune-mediated cytotoxicity via antibody-dependent cellular cytotoxicity (ADCC) — a process in which immune cells are directed to attack tumor cells

Beyond simple receptor blockade, trastuzumab modulates downstream pathways such as PI3K/AKT and MAPK. Through these actions, trastuzumab reduces proliferation and enhances apoptosis (programmed cell death). These multimodal effects distinguish trastuzumab from small-molecule tyrosine kinase inhibitors. These effects also partially explain its durable clinical efficacy despite the emergence of resistance mechanisms.

Key Clinical Trials of Trastuzumab

The clinical development of trastuzumab marked a turning point in precision oncology. The first pivotal evidence of benefit emerged from a landmark randomized trial in metastatic HER2-overexpressing breast cancer. This trial demonstrated that adding trastuzumab to chemotherapy significantly improved response rates, progression-free survival (PFS), and overall survival (OS). This trial established HER2 as a predictive biomarker and validated targeted therapy as a therapeutic paradigm.

Importantly, this study also highlighted early safety concerns, particularly cardiotoxicity (heart damage) when trastuzumab was combined with anthracyclines. This issue would shape subsequent trial designs and clinical practice. A subsequent study (M77001) confirmed the benefit of combining trastuzumab with docetaxel in the first-line metastatic setting. This finding reinforced the concept that HER2 blockade synergizes with cytotoxic therapy.

The translation of trastuzumab into early-stage disease was rapidly pursued. It remains one of the most successful examples of adjuvant targeted therapy. Adjuvant therapy is treatment given after initial surgery to reduce the risk of recurrence. The HERA trial established one year of adjuvant trastuzumab following chemotherapy as a standard of care. This trial demonstrated significant improvements in disease-free survival (DFS) and overall survival.

Notably, while longer durations of therapy were explored, no additional survival benefit was observed beyond one year. This finding underscores the importance of balancing efficacy with toxicity and cost.

Parallel North American trials (NSABP B-31 and NCCTG N9831) showed that concurrent administration of trastuzumab with taxane-based chemotherapy resulted in marked improvements in DFS and OS compared with chemotherapy alone. These trials differed in sequencing and design, yet converged on similar conclusions. This convergence strengthened the robustness of the evidence. However, the authors caution that cross-trial comparisons should be interpreted cautiously due to differences in patient populations and chemotherapy backbones.

The BCIRG 006 trial further refined treatment strategies by comparing anthracycline-containing and non-anthracycline regimens. While efficacy outcomes were broadly comparable, the non-anthracycline regimen (docetaxel, carboplatin, and trastuzumab) demonstrated a more favorable cardiac safety profile. This finding provided a critical alternative for patients at increased cardiovascular risk. This finding has had lasting clinical implications, particularly in tailoring therapy for older patients or those with other medical conditions. Nevertheless, subtle differences in long-term outcomes and patient selection criteria suggest that regimen choice should remain individualized rather than universally standardized.

In the neoadjuvant setting (treatment given before surgery), trastuzumab has enabled significant improvements in pathological complete response (pCR). Pathological complete response means no detectable cancer cells remain in the tissue removed during surgery. This endpoint is associated with long-term outcomes in HER2-positive disease. The NOAH trial demonstrated that the addition of trastuzumab to chemotherapy significantly increased pCR rates and event-free survival in locally advanced and inflammatory breast cancer.

The NeoSphere trial extended these findings by introducing dual HER2 blockade with trastuzumab and pertuzumab. This dual approach showed higher pCR rates compared with single-agent HER2 targeting. While pCR is an attractive early endpoint, its correlation with long-term survival varies across subtypes and treatment contexts. The authors note that caution is warranted when extrapolating short-term results to definitive clinical benefit.

The adjuvant landscape has further evolved with the incorporation of dual HER2 blockade. The APHINITY trial demonstrated that adding pertuzumab to trastuzumab and chemotherapy modestly improved invasive DFS. The greatest benefit was observed in node-positive patients. The relatively small absolute benefit, however, raises important questions regarding cost-effectiveness and patient selection. This finding emphasizes the need for biomarker-driven refinement. Notably, long-term follow-up of APHINITY has reinforced the durability of benefit, particularly in high-risk populations. This follow-up has also highlighted the generally manageable safety profile of dual HER2-targeted therapy.

In contrast, the KATHERINE trial addressed patients with residual disease after neoadjuvant therapy. This trial showed that switching from trastuzumab to trastuzumab emtansine (T-DM1) significantly improved invasive DFS. This study exemplifies response-adapted therapy. It also highlights the limitations of trastuzumab monotherapy in high-risk, treatment-resistant populations. These results support the use of residual disease as a predictive biomarker for treatment escalation.

Neoadjuvant therapy strategies have also evolved, as highlighted by the GeparSepto-GBG69 trial. This trial compared nab-paclitaxel with solvent-based paclitaxel in combination with standard neoadjuvant regimens for early breast cancer. The study demonstrated higher pathological complete response rates with nab-paclitaxel, particularly in aggressive subtypes such as HER2-positive and triple-negative tumors. This finding underscores the importance of optimizing chemotherapy backbones to enhance HER2-targeted therapy efficacy. These findings have informed subsequent neoadjuvant strategies, supporting individualized treatment selection based on tumor biology and anticipated response.

In metastatic disease, trastuzumab remains a foundational component of first-line therapy. The CLEOPATRA trial established the combination of trastuzumab, pertuzumab, and docetaxel as a standard of care. This trial demonstrated substantial improvements in both PFS and OS. The magnitude and durability of benefit observed in this trial are notable. However, patient selection (for example, exclusion of prior anti-HER2 therapy in the metastatic setting) may limit generalizability to contemporary populations. These populations are increasingly exposed to trastuzumab earlier in the disease course.

Subsequent lines of therapy have been transformed by antibody-drug conjugates such as T-DM1 (EMILIA trial) and trastuzumab deruxtecan (DESTINY-Breast03). Both agents build upon the trastuzumab backbone to deliver cytotoxic payloads directly to HER2-expressing cells. These agents have demonstrated superior efficacy compared with earlier standards. However, differences in toxicity profiles, particularly interstitial lung disease with trastuzumab deruxtecan, necessitate careful monitoring. Moreover, evolving evidence supports the sequential use of these agents based on prior HER2-directed therapies and patient tolerability. This approach further personalizes metastatic treatment.

A particularly significant development is the expansion of HER2-targeted therapy into the HER2-low population, as demonstrated in the DESTINY-Breast04 trial. This study showed that trastuzumab deruxtecan significantly improved PFS and OS compared with chemotherapy in patients with low HER2 expression (IHC 1+ or 2+/ISH-negative). This finding effectively redefines HER2 as a spectrum rather than a binary biomarker. While trastuzumab itself has limited activity in this subgroup, its role as a targeting moiety in antibody-drug conjugates underscores its continued relevance. These findings challenge traditional classification systems. They also highlight the dynamic interplay between diagnostic criteria, therapeutic innovation, and the need for precise biomarker testing. Ongoing studies are now evaluating combination strategies in HER2-low disease, including integration with endocrine therapy and immunotherapy.

Resistance to Trastuzumab

Despite its transformative impact, resistance to trastuzumab remains a major clinical challenge. Mechanisms of resistance include:

• Alterations in the HER2 receptor, such as truncated forms like p95HER2
• Activation of alternative signaling pathways, such as PI3K mutations or PTEN loss
• Immune evasion

These resistance pathways have driven the development of combination strategies. Such strategies include dual HER2 blockade, integration with CDK4/6 inhibitors, and PI3K pathway targeting. While the preclinical rationale is strong, clinical results have been heterogeneous. This heterogeneity reflects the complexity of tumor biology and the need for more precise biomarker-driven approaches. Novel strategies, including antibody-drug conjugates and bispecific antibodies, are being investigated to overcome these resistance mechanisms. These approaches provide hope for patients with refractory disease.

Safety and Side Effects of Trastuzumab

The safety profile of trastuzumab is generally favorable compared with conventional chemotherapy. However, cardiotoxicity remains the most clinically significant adverse effect. Unlike anthracycline-induced cardiomyopathy, trastuzumab-associated cardiac dysfunction is often reversible and not dose-dependent. Despite this, it necessitates regular cardiac monitoring.

Infusion-related reactions are relatively common, particularly during the first administration. These reactions are typically manageable with premedication and supportive care. Long-term tolerability has facilitated extended use in both adjuvant and metastatic settings. However, cumulative toxicity and patient quality of life must be considered in treatment planning.

Importantly, subcutaneous formulations of trastuzumab have demonstrated equivalent efficacy with improved patient convenience. This convenience may enhance adherence in real-world practice.

In contemporary practice, trastuzumab serves not only as a therapeutic agent but also as a platform for drug development. It forms the backbone of multiple combination regimens and antibody-drug conjugates. Its integration with other targeted therapies, including CDK4/6 and PI3K inhibitors, reflects an evolving paradigm. In this paradigm, HER2 signaling is considered within a broader network of oncogenic pathways. However, variability in trial design, patient populations, and endpoints complicates cross-study comparisons. This variability highlights the importance of critical interpretation when translating evidence into clinical decision-making. Adaptive trial designs and biomarker-enriched cohorts are increasingly leveraged to optimize both efficacy and safety outcomes.

Abemaciclib: Targeting the Cell Cycle in Hormone Receptor-Positive Cancer

Hormone receptor-positive breast cancers account for nearly 70% of diagnosed cases. These cancers are typically driven by estrogen-dependent signaling pathways. For this reason, they are commonly treated with endocrine therapies such as aromatase inhibitors or selective ER modulators.

Nevertheless, endocrine resistance frequently develops during disease progression. One of the key mechanisms underlying this resistance involves dysregulation of the cyclin D-CDK4/6-retinoblastoma (Rb) signaling axis. This dysregulation promotes uncontrolled cell cycle progression and sustained tumor proliferation.

The development of selective CDK4/6 inhibitors, including abemaciclib, palbociclib, and ribociclib, has therefore represented a major therapeutic advance in HR-positive breast cancer management. By blocking CDK4/6 activity and restoring cell cycle control, these agents enhance the efficacy of endocrine therapy. They also significantly prolong progression-free survival across multiple clinical trials.

Alpelisib: Targeting the PI3K Pathway

The PI3K/AKT/mTOR signaling pathway represents another critical regulatory network involved in breast cancer development. Activating mutations in the PIK3CA gene and other upstream alterations frequently lead to constitutive activation of this pathway. Constitutive activation means the pathway is switched on permanently. This activation promotes tumor growth, metabolic adaptation, and resistance to endocrine or HER2-directed therapies.

As a result, pharmacological inhibition of PI3K signaling has emerged as an important therapeutic strategy. Alpelisib is a selective inhibitor of the PI3K alpha isoform. Alpelisib has demonstrated significant clinical benefit in patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer when administered in combination with endocrine therapy.

These findings highlight the growing importance of genomic testing and biomarker-guided treatment selection in modern breast cancer management.

The Challenge of Treatment Resistance

Despite the substantial progress achieved through targeted therapies, several challenges continue to limit long-term treatment success. Both intrinsic and acquired resistance frequently arise during therapy. This resistance is often driven by compensatory signaling pathways, tumor microenvironment interactions, or clonal evolution within the tumor cell population. Clonal evolution means that different groups of cancer cells within the same tumor change over time.

Furthermore, the complex interplay between tumor cells, immune components, and stromal elements within the tumor microenvironment can influence therapeutic response and contribute to disease progression. Ongoing research efforts are therefore focused on identifying predictive biomarkers, optimizing treatment sequencing, and developing rational combination strategies. These strategies aim to overcome resistance mechanisms and improve durable clinical responses.

Beyond conventional HER2-targeted strategies, emerging approaches include combination therapies integrating trastuzumab with immune checkpoint inhibitors. These combinations aim to enhance ADCC and promote antitumor immune responses. In parallel, antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan represent a major therapeutic advancement. These agents couple HER2 targeting with intracellular delivery of cytotoxic payloads. This design extends clinical benefit even to tumors with low HER2 expression.

What This Means for Patients

This review demonstrates that breast cancer treatment is no longer based on a single approach for all patients. Instead, treatment is increasingly guided by the specific molecular features of each patient's tumor.

For patients with HER2-positive breast cancer, trastuzumab remains the cornerstone of treatment. It has improved survival in both early-stage and metastatic disease. The development of antibody-drug conjugates has further expanded options, even for patients whose tumors express low levels of HER2.

For patients with hormone receptor-positive breast cancer, CDK4/6 inhibitors such as abemaciclib offer a significant advance. These drugs enhance the effectiveness of endocrine therapy and prolong the time before the disease progresses.

For patients whose tumors carry a PIK3CA mutation, alpelisib provides meaningful benefit when combined with endocrine therapy. This benefit highlights the importance of genomic testing to identify which patients are most likely to respond to specific targeted treatments.

The authors emphasize that molecular diagnostics are now central to clinical decision-making. This includes selecting which patients should receive which treatments, understanding how resistance develops, and determining the best sequence of therapies.

Limitations of the Evidence

The authors acknowledge several limitations in the current evidence base. Variability in trial design, patient populations, and endpoints complicates comparisons across studies. Cross-trial comparisons should be interpreted cautiously due to differences in patient populations and chemotherapy backbones.

While pathological complete response is an attractive early endpoint, its correlation with long-term survival varies across subtypes and treatment contexts. Caution is warranted when extrapolating short-term results to definitive clinical benefit.

Patient selection criteria in some trials may limit generalizability to contemporary populations. For example, the CLEOPATRA trial excluded patients who had received prior anti-HER2 therapy in the metastatic setting. This exclusion may limit how well the results apply to patients who are increasingly exposed to trastuzumab earlier in their disease course.

Additionally, while the preclinical rationale for combination strategies is strong, clinical results have been heterogeneous. This heterogeneity reflects the complexity of tumor biology and the need for more precise biomarker-driven approaches.

Recommendations and Future Directions

The authors conclude that ongoing clinical and translational research will be critical to refine combination strategies, overcome resistance mechanisms, and identify predictive biomarkers. These efforts aim to further optimize patient outcomes.

Key recommendations and areas of focus include:

1. Biomarker-driven treatment selection — using molecular testing to match patients with the most appropriate targeted therapies
2. Optimizing treatment sequencing — determining the best order in which to use available therapies
3. Developing rational combination strategies — combining agents that target different pathways to overcome resistance
4. Liquid biopsy monitoring — using circulating tumor DNA to track resistance in real time and adapt treatment
5. Adaptive trial designs — using biomarker-enriched cohorts to optimize both efficacy and safety outcomes
6. Expanding HER2-targeted therapy — including antibody-drug conjugates for HER2-low disease and combination approaches with endocrine therapy and immunotherapy

The integration of these agents into biomarker-driven, multimodal treatment frameworks underscores a paradigm shift toward personalized cancer care. This shift applies across breast and gynecologic malignancies. The authors emphasize that particular attention must be given to the translation of molecular diagnostics into clinical decision-making. This includes patient selection, understanding resistance mechanisms, and sequencing strategies within evolving precision oncology frameworks.

Frequently Asked Questions

What is targeted therapy for breast cancer?

Targeted therapies are drugs designed to selectively block specific oncogenic signaling networks — the communication systems inside cells that drive cancer growth. This review examines three such drugs: trastuzumab, abemaciclib, and alpelisib. Each blocks a different molecular pathway. Treatment is increasingly guided by the specific molecular features of each patient's tumor, rather than a single approach for all patients.

What does it mean if my tumor is HER2-positive?

HER2-positive disease is defined by amplification or overexpression of the ERBB2 gene. It occurs in approximately 15-20% of breast cancers and is associated with aggressive tumor biology and unfavorable prognosis in the absence of targeted intervention. Trastuzumab, a humanized monoclonal antibody directed against the HER2 receptor, remains the foundation of treatment for HER2-positive breast cancer and has improved survival in both early-stage and metastatic disease.

What are the side effects of trastuzumab?

The safety profile of trastuzumab is generally favorable compared with conventional chemotherapy. However, cardiotoxicity remains the most clinically significant adverse effect. Unlike anthracycline-induced cardiomyopathy, trastuzumab-associated cardiac dysfunction is often reversible and not dose-dependent, but it necessitates regular cardiac monitoring. Infusion-related reactions are relatively common, particularly during the first administration, and are typically manageable with premedication and supportive care.

What is abemaciclib and who might benefit from it?

Abemaciclib is a selective CDK4/6 inhibitor. Hormone receptor-positive breast cancers account for nearly 70% of diagnosed cases and are typically driven by estrogen-dependent signaling. Endocrine resistance frequently develops, partly through dysregulation of the cyclin D-CDK4/6-retinoblastoma signaling axis. By blocking CDK4/6 activity and restoring cell cycle control, abemaciclib enhances the efficacy of endocrine therapy and significantly prolongs progression-free survival across multiple clinical trials.

What is alpelisib and why does PIK3CA testing matter?

Alpelisib is a selective inhibitor of the PI3K alpha isoform. Activating mutations in the PIK3CA gene frequently lead to constitutive activation of the PI3K/AKT/mTOR pathway, promoting tumor growth and resistance to endocrine or HER2-directed therapies. Alpelisib has demonstrated significant clinical benefit in patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer when administered in combination with endocrine therapy. This highlights the growing importance of genomic testing and biomarker-guided treatment selection.

What happens if my breast cancer becomes resistant to treatment?

Both intrinsic and acquired resistance frequently arise during therapy. Intrinsic resistance means the tumor does not respond from the start; acquired resistance means it initially responds but later stops. Resistance is often driven by compensatory signaling pathways, tumor microenvironment interactions, or clonal evolution. Ongoing research focuses on identifying predictive biomarkers, optimizing treatment sequencing, and developing rational combination strategies to overcome resistance mechanisms and improve durable clinical responses.

When should a patient with HER2-positive, hormone receptor-positive, or PIK3CA-mutated breast cancer seek a second opinion?

A second opinion is worth considering when molecular testing has not clearly established your subtype or biomarker status, since trastuzumab depends on HER2 amplification or overexpression, abemaciclib on hormone receptor-positive disease, and alpelisib on a PIK3CA mutation. It is also reasonable when the proposed regimen, sequencing, or cardiac monitoring plan is unclear, or when residual disease after neoadjuvant therapy raises the question of switching to trastuzumab emtansine. Because trial results vary by patient population and prior treatment, an independent review of your pathology and records can clarify whether the recommended approach fits your tumor profile. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Molecular Profiling and Targeted Therapeutic Strategies in Breast Cancer: Clinical Integration of HER2, CDK4/6, and PI3K Inhibition with Trastuzumab, Abemaciclib and Alpelisib.

Authors: Kawczak P, Bączek T.

Author affiliations: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, 80-416 Gdańsk, Poland; Department of Nursing and Medical Rescue, Institute of Health Sciences, Pomeranian University in Słupsk, 76-200 Słupsk, Poland

Publication: Journal of Clinical Medicine (J. Clin. Med.), 2026, Volume 15, Article 3715

DOI: https://doi.org/10.3390/jcm15103715

Article type: Review

Publication dates: Received 16 April 2026; Revised 6 May 2026; Accepted 10 May 2026; Published 12 May 2026

Academic editor: Lorenzo Scardina

Keywords: breast cancer; trastuzumab; abemaciclib; alpelisib; HER2; CDK4/6; PI3K; targeted therapy; precision oncology; molecular pathways

This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace consultation with a qualified healthcare professional. Patients should discuss their individual treatment options with their oncology team.